compound | μM | A-V | Q-T | QRS |
---|---|---|---|---|
paclitaxel | 10 | 99.1 ± 1.7 | 109.1 ± 2.3 | 99.6 ± 3.4 |
20 | 111.2 ± 7.3 | 112.8 ± 7.6 | 108.0 ± 3.1 | |
docetaxel | 20 | 93.5 ± 6.0 | 99.0 ± 3.9 | 97.0 ± 2.6 |
taxol B | 20 | 100.2 ± 1.8 | 100.8 ± 2.6 | 99.5 ± 3.2 |
taxol C | 20 | 111.2 ± 7.9 | 114.0 ± 6.8 | 102.5 ± 6.3 |
N-methyltaxol C | 10 | 97.6 ± 3.1 | 102.8 ± 0.9 | 100.8 ± 2.8 |
20 | 111.6 ± 8.7 | 108.2 ± 7.0 | 107.8 ± 1.9 |
A-V, Q-T and QRS intervals were expressed as the mean ± SE % of the prechallenge value. No statistically significant difference was found between hearts treated with paclitaxel or derivatives in comparison with those perfused with 1 μl/ml DMSO, used as control. Baseline values were: atrioventricular conduction time (A-V) = 78.4 ± 2.3 ms; Q-T interval (Q-T) = 171.0 ± 9.8 ms; duration of QRS complex (QRS) = 14.7 ± 0.8 ms.